<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02427867</url>
  </required_header>
  <id_info>
    <org_study_id>PRINCE/43/OSR</org_study_id>
    <nct_id>NCT02427867</nct_id>
  </id_info>
  <brief_title>Ischaemic PReconditioning In Non Cardiac surgEry</brief_title>
  <acronym>PRINCE</acronym>
  <official_title>Ischaemic PReconditioning In Non Cardiac surgEry</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Università Vita-Salute San Raffaele</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Università Vita-Salute San Raffaele</source>
  <brief_summary>
    <textblock>
      Several randomized trials suggested a cardioprotective beneficial effect (eg reduction in&#xD;
      cardiac troponin release) of remote ischemic preconditioning in cardiac surgery.&#xD;
&#xD;
      Remote ischemic preconditioning by brief episodes of ischemia and reperfusion in a remote&#xD;
      organ or vascular territory provides protection from injury by myocardial ischemia and&#xD;
      reperfusion. In the translation of remote ischemic preconditioning from bench to bedside, the&#xD;
      first proof of principle and small randomized controlled trials have shown a decreased&#xD;
      release of myocardial biomarkers after aortic, congenital cardiac, adult valve and coronary&#xD;
      artery by-pass graft surgery. This reduction in cardiac biomarkers release translated into&#xD;
      better survival in a recent randomized trial performed in cardiac surgery. No clinical trial&#xD;
      on remote ischemic preconditioning in non-cardiac surgery setting has been performed so far.&#xD;
&#xD;
      The investigators study wants to test, for the first time, the hypothesis that remote&#xD;
      ischaemic preconditioning is effective in reducing cardiac damage in high risk patients&#xD;
      undergoing non-cardiac surgery. Remote ischaemic preconditioning will be achieved by&#xD;
      inflation of a blood-pressure cuff to 200 mm Hg to the upper arm for 5 minutes, followed by 5&#xD;
      minutes reperfusion while the cuff will be deflated. General anesthesia will be induced and&#xD;
      maintained without using propofol in both groups. Cardiac troponin will be used as marker of&#xD;
      cardiac damage. If the results of a reduction in postoperative cardiac troponin release and&#xD;
      perioperative cardiac ischaemic events will be confirmed in a non-cardiac surgery setting,&#xD;
      the investigators could improve a strategy to prevent perioperative cardiac complication easy&#xD;
      to apply, safe and low cost.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2015</start_date>
  <completion_date type="Anticipated">June 2023</completion_date>
  <primary_completion_date type="Anticipated">May 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>cardiac troponin</measure>
    <time_frame>Hospital - approximately 1 week</time_frame>
    <description>elevation of cardiac troponin after non-cardiac surgery</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">1100</enrollment>
  <condition>Myocardial Ischemia</condition>
  <condition>Surgery</condition>
  <arm_group>
    <arm_group_label>remote ischemic preconditioning</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Three cycles of 5 minutes ischemia will be applied to the upper left arm (or right arm or legs if the left arm will not be deemed suitable by the attending physician), achieved by inflation of a blood-pressure cuff to 200 mm Hg, followed by 5 minutes reperfusion while the cuff will be deflated.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>no ischemic preconditioning</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>The cuff will be placed around the arm but not inflated.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Remote ischemic preconditioning</intervention_name>
    <arm_group_label>remote ischemic preconditioning</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>no ischemic preconditioning</intervention_name>
    <arm_group_label>no ischemic preconditioning</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  written informed consent&#xD;
&#xD;
          -  intermedial and high risk non cardiac surgery&#xD;
&#xD;
          -  general anesthesia&#xD;
&#xD;
          -  ongoing or recently suspended antiplatelet therapy&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  pregnancy&#xD;
&#xD;
          -  planned locoregional anesthesia without general anesthesia&#xD;
&#xD;
          -  unstable or ongoing angina&#xD;
&#xD;
          -  recent (&lt; 1 month) or ongoing acute myocardial infarction&#xD;
&#xD;
          -  inclusion in other randomised controlled studies in the previous 30 days&#xD;
&#xD;
          -  peripheral vascular disease affecting the upper limbs&#xD;
&#xD;
          -  cardiac surgery&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alberto Zangrillo, Prof.</last_name>
    <role>Study Chair</role>
    <affiliation>Vita-Salute University of Milan</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Giovanni Landoni, Prof.</last_name>
    <phone>+39022643</phone>
    <phone_ext>6151</phone_ext>
    <email>landoni.giovanni@hsr.it</email>
  </overall_contact>
  <location>
    <facility>
      <name>IRCCS San Raffaele Scientific Institute</name>
      <address>
        <city>Milan</city>
        <state>MI</state>
        <zip>20132</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Giovanni Landoni</last_name>
      <email>landoni.giovanni@hsr.it</email>
    </contact>
    <investigator>
      <last_name>Massimo Zambon, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Laura Pasin, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <reference>
    <citation>Thielmann M, Kottenberg E, Kleinbongard P, Wendt D, Gedik N, Pasa S, Price V, Tsagakis K, Neuhäuser M, Peters J, Jakob H, Heusch G. Cardioprotective and prognostic effects of remote ischaemic preconditioning in patients undergoing coronary artery bypass surgery: a single-centre randomised, double-blind, controlled trial. Lancet. 2013 Aug 17;382(9892):597-604. doi: 10.1016/S0140-6736(13)61450-6. Erratum in: Lancet. 2013 Sep 14;382(9896):940.</citation>
    <PMID>23953384</PMID>
  </reference>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>April 15, 2015</study_first_submitted>
  <study_first_submitted_qc>April 22, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 28, 2015</study_first_posted>
  <last_update_submitted>September 29, 2021</last_update_submitted>
  <last_update_submitted_qc>September 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 30, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Università Vita-Salute San Raffaele</investigator_affiliation>
    <investigator_full_name>Giovanni Landoni</investigator_full_name>
    <investigator_title>MD, Associate Professor</investigator_title>
  </responsible_party>
  <keyword>remote ischemic preconditioning</keyword>
  <keyword>non cardiac surgery</keyword>
  <keyword>myocardial ischemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Ischemia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

